<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Efavirenz</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00625</strong>&#160; (APRD00059, DB07709)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Efavirenz (brand names Sustiva&#174; and Stocrin&#174;) is a non-nucleoside reverse transcriptase inhibitor (<span class="caps">NNRTI</span>) and is used as part of highly active antiretroviral therapy (<span class="caps">HAART</span>) for the treatment of a human immunodeficiency virus (<span class="caps">HIV</span>) type 1.</p>
<p>For <span class="caps">HIV</span> infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred <span class="caps">NNRTI</span>-based regimen.</p>
<p>Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent <span class="caps">HIV</span> transmission for those exposed to materials associated with a high risk for <span class="caps">HIV</span> transmission.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00625/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00625/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00625.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00625.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00625.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00625.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00625.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00625">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Efavirenz</td><td>German/Spanish</td><td>INN</td></tr><tr><td>&#201;favirenz</td><td>French</td><td>INN</td></tr><tr><td>Efavirenzum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>E.F</td><td>McNeil &amp; Argus</td></tr><tr><td>Efavir</td><td>Cipla</td></tr><tr><td>Efavirenz</td><td>Aspen Pharmacare</td></tr><tr><td>Efcure</td><td>Emcure Pharmaceuticals</td></tr><tr><td>Efferven</td><td>Ranbaxy Laboratories</td></tr><tr><td>Estiva</td><td>Hetero</td></tr><tr><td>Evirenz</td><td>Alkem Laboratories</td></tr><tr><td>Stocrin</td><td>Merck &amp; Co.</td></tr><tr><td>Sustiva</td><td>Bristol-Myers Squibb</td></tr><tr><td>Viranz</td><td>Aurobindo Pharma</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-hiv-agents">Anti-HIV Agents</a></li>
<li><a href="/mesh/reverse-transcriptase-inhibitors">Reverse Transcriptase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>154598-52-4</td></tr><tr><th>Weight</th><td>Average: 315.675<br>Monoisotopic: 315.027390859</td></tr><tr><th>Chemical Formula</th><td>C<sub>14</sub>H<sub>9</sub>ClF<sub>3</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>XPOQHMRABVBWPR-ZDUSSCGKSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzoxazines</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzoxazines</td></tr><tr><th>Alternative parents</th><td>Chlorobenzenes; Aryl Chlorides; Ynones; Carbamic Acids and Derivatives; Polyamines; Organochlorides; Organofluorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; aryl chloride; ynone; benzene; aryl halide; carbamic acid derivative; polyamine; organohalogen; organochloride; organofluoride; organonitrogen compound; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-member aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in combination treatment of HIV infection (AIDS)</td></tr><tr><th>Pharmacodynamics</th><td>Efavirenz (dideoxyinosine, ddI) is an oral nucleoside reverse transcriptase inhibitor (NRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection.</td></tr><tr><th>Mechanism of action</th><td>Similar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>99.5-99.75%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1.</p></td></tr><tr><th>Route of elimination</th><td>Nearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites.</td></tr><tr><th>Half life</th><td>40-55 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9964</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9182</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5553</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7617</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7451</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9557</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9157</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8033</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6037</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6996</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6975</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8699</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5291</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7577</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6705</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6991
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8997
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5416 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9617
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9098
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bristol myers squibb co</li>
<li>Bristol myers squibb pharma co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Apotheca Inc.</li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Efavirenz decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Efavirenz may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Efavirenz decreases levels of clarithromycin</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Efavirenz decreases the levels of cyclosporine</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Efavirenze may increase the adverse/toxic effects of dihydroergotamine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Affects hepatic enzyme CYP2C9/10 metabolism and may increase the level of eltrombopag. </td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>The antiretroviral agent may increase the ergot derivative toxicity</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine, when used concomitantly with Efavirenz, may experience a  significant decrease in plasma levels and a loss of efficacy. 
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Efavirenz decreases the effect of indinavir</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Efavirenz may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Efavirenz may decrease the serum concentration of methadone by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of methadone if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>The antiretroviral agent may increase the ergot derivative toxicity</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>The antiretroviral agent may increase the ergot derivative toxicity</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Concentration of rilpivirine decreases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's. </td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Efavirenz decreases the effect of saquinavir</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Efavirenz may decrease the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort decreases the antiretroviral effect</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Inducers of CYP3A enzymes will decrease telaprevir levels. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Efavirenz may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Efavirenze may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of efavirenz by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased efavirenz adverse effects during concomitant therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid excessive or chronic alcohol consumption.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>